Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Prodomal Bullous Pemphigoid and Atypical Presentations

Description

The lecture focuses on various atypical presentations of bullous pemphigoid, an autoimmune blistering disease often seen in individuals over 60. This condition is primarily characterized by the formation of tense bullae and significant pruritus. However, there are lesser-known variants such as pruritus pemphigoid, localized bullous pemphigoid, and even cases that present with exanthematous or urticarial plaques rather than bullae. The speaker highlights the diagnostic challenges posed by these non-bullous manifestations, noting that a study found 36.8% of cases presented without typical blistering. Diagnostic approaches include serological tests and skin biopsies, as direct immunofluorescence can be crucial in confirming diagnosis. The discussion also touches on drug-induced bullous pemphigoid, linking various medications with this condition. Treatment strategies, although not elaborated on in detail, are acknowledged as critical and can be discussed in future sessions. Overall, the lecture emphasizes the importance of recognizing these atypical forms to prevent misdiagnosis and ensure appropriate management.

View more

Conclusions

  • Bullous pemphigoid primarily affects elderly patients and is characterized by a strong immune response to specific BP antigens.
  • Non-bullous variants of bullous pemphigoid can present initially, complicating diagnosis and leading to treatment challenges.
  • A significant proportion (36.8%) of cases may present without bullae, often requiring aggressive steroid treatment.
  • Variants such as pruritic pemphigoid and lichen planus pemphigoides may mimic other conditions and necessitate careful diagnostic assessment.
  • Dipeptidyl peptidase IV inhibitors have been identified as a risk factor for developing bullous pemphigoid.
  • Effective treatment often requires a multimodal approach, including high-dose steroids, immunosuppressants, and biologics for severe cases.
  • Beek N et al. Expert Rev Clin Immunol. (2016)
  • AH et al. Arch Dermatol Res. (2018)
  • R et al. J Dermatol Sci. (2015)
  • Schauer et al. Br J Dermatol. 2018 Sept 06. doi:10.111/bjd (Epub)
  • J dermatol. 2017 Jul;44(7):742-746.
  • Alonzo-Llamazares J, et al. Int J Dermatol. 1998 Jul;37(7):508-14.
  • Schacter M, Brieva J, Jones JC, Zillikens D, Skrobek C, Chan LS. Pemphigoid Nodularis associated with autoantibodies to the NC16A domain of BP180 and a hyperproliferate integrin profile. J Am Acad Dermatol. 2001 Nov;45(5):747-54.
  • Sakuma-Oyama Y, et al. Clin Exp Dermatol. 2003 Nov;28(6):613-6.
  • Garcia-Diez, et al. Actas Dermosifiliogr. 2017 Jan-Feb;108(1)e1-e5.
  • Benzaquen M, et al. J Am Acad Dermatol. 2018;Vol 78, Number 6; 1090-1099.